Keith C. Bible, M.D., Ph.D., combines clinical practice as a medical oncologist with basic, translational and clinical research initiatives directed toward the ultimate goal of improving therapies for patients afflicted with cancer.
- Discovering and developing therapeutics targeting redox pathways as means of selectively killing cancer cells
- Improving knowledge of how cancer cells develop resistance to cancer therapies with the goal of circumventing such resistance
- Identifying abnormalities associated with thyroid cancers, ovarian cancer and multiple myeloma with potential to lead to discoveries intended to improve therapy for these diseases
- Developing innovative clinical trials with the goal of improving outcomes for cancer patients
Significance to patient care
Dr. Bible's research focuses on the discovery and development of novel small molecules as cancer therapeutics, with emphasis on elaboration of underlying mechanisms of action as an approach to gaining insights into cancer pathogenesis and additional novel therapeutic opportunities.
- Chair, Endocrine Malignancies Disease-Oriented Group, Mayo Clinic Cancer Center
- Chair, Endocrine Malignancies and General Tumor Groups, Division of Medical Oncology, Mayo Clinic in Rochester, Minn.
- Member, Differentiated Thyroid Carcinoma Management Guidelines and Anaplastic Thyroid Carcinoma Management Guidelines Task Forces, American Thyroid Association
- Member — International Thyroid Oncology Group, Endocrine Society, American Association for Cancer Research, American Society of Clinical Oncology
- Member, multiple study sections, National Institutes of Health